KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Assets (2016 - 2025)

Pfizer (PFE) has disclosed Assets for 17 consecutive years, with $208.2 billion as the latest value for Q4 2025.

  • Quarterly Assets fell 2.45% to $208.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $208.2 billion through Dec 2025, down 2.45% year-over-year, with the annual reading at $208.2 billion for FY2025, 2.45% down from the prior year.
  • Assets for Q4 2025 was $208.2 billion at Pfizer, roughly flat from $208.7 billion in the prior quarter.
  • The five-year high for Assets was $226.5 billion in Q4 2023, with the low at $41.1 billion in Q4 2022.
  • Average Assets over 5 years is $186.6 billion, with a median of $207.0 billion recorded in 2025.
  • The sharpest move saw Assets dropped 11.22% in 2022, then soared 422.64% in 2023.
  • Over 5 years, Assets stood at $181.5 billion in 2021, then grew by 8.67% to $197.2 billion in 2022, then increased by 14.86% to $226.5 billion in 2023, then dropped by 5.79% to $213.4 billion in 2024, then fell by 2.45% to $208.2 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $208.2 billion, $208.7 billion, and $206.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.